← Eichor
Condition: Prostate Cancer Metastatic Disease Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Prostate Cancer Metastatic Disease

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPC
Phase 3 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT05956639A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
Phase 1/Phase 2 · 18 location(s) · Pathos AI, Inc. · NCT06785636Study of AZD0754 in Participants With Metastatic Prostate Cancer
Phase 1/Phase 2 · 15 location(s) · AstraZeneca · NCT06267729A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer
Phase 1/Phase 2 · 12 location(s) · Memorial Sloan Kettering Cancer Center · NCT06457919Prospective Evaluation of Imaging Response Biomarkers During [177Lu]Lu-PSMA in Metastatic Castration-resistant Prostate
Phase N/A · 1 location(s) · University Hospital, Grenoble · NCT06828263Intestinal Akkermansia Muciniphila in Prostate Cancer
Phase N/A · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT06242509A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or M
Phase 1/Phase 2 · 4 location(s) · Genentech, Inc. · NCT07567846Evaluating In Home Cancer Therapy Versus In Clinic Cancer Therapy in Black Men With Locally Advanced, Biochemically Recu
Phase 2 · 1 location(s) · Mayo Clinic · NCT07073794Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
Phase 2 · 18 location(s) · VA Office of Research and Development · NCT04038502LUtetium-177 DOsimetry as a Predictive Biomarker of Response in Metastatic Prostate Cancer Patients Treated With PSMA Ra
Phase N/A · 1 location(s) · Jules Bordet Institute · NCT07370597PSMA PET-Guided Progression-Directed Radiotherapy for Oligoprogressive Prostate Cancer
Phase N/A · 1 location(s) · Affidea Nu-med Center of Oncological DIagnostics and Therapy · NCT07691697High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
Phase 2 · 17 location(s) · VA Office of Research and Development · NCT05011383A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastati
Phase 1/Phase 2 · 1 location(s) · CuraCell TX AB · NCT07255664ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium
Phase 1/Phase 2 · 1 location(s) · University College, London · NCT07414940Working Out M0 Bipolar Androgen Therapy
Phase 2 · 12 location(s) · Australian and New Zealand Urogenital and Prostate Cancer Tr · NCT06594926ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials
Phase N/A · 3 location(s) · Duke University · NCT06141993Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors
Phase 1 · 2 location(s) · Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd · NCT06666270177Lu-P17-087/177Lu-P17-088 in Patients With Metastatic Castration-resistant Prostate Cancer
EARLY_Phase 1 · 1 location(s) · Peking Union Medical College Hospital · NCT05603559PSMA PET for Surveillance After Focal Therapy
NA · 1 location(s) · University of Chicago · NCT07115914Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
Phase 2 · 1 location(s) · Mayo Clinic · NCT06200103A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
Phase 1 · 8 location(s) · Bristol-Myers Squibb · NCT06067841An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic H
Phase 2 · 67 location(s) · Novartis Pharmaceuticals · NCT06991556A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Re
Phase 1/Phase 2 · 82 location(s) · Merck Sharp & Dohme LLC · NCT06863272A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (
Phase 1 · 19 location(s) · Daiichi Sankyo · NCT07244341A Clinical Study on the Efficacy and Safety of Fasudil Hydrochloride Combined With Immunotherapy in the Treatment of Met
Phase 2 · 1 location(s) · baotai Liang · NCT07250542Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc
Phase 2 · 4 location(s) · VA Office of Research and Development · NCT06084338This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Tor
Phase 1 · 3 location(s) · Zumutor Biologics Inc. · NCT06451497A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resist
Phase 3 · 329 location(s) · Merck Sharp & Dohme LLC · NCT06136650FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer,
Phase 2 · 6 location(s) · Northwestern University · NCT06244004Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients
Phase 3 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT06350825
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.